Bremelanotide is a synthetic cyclic heptapeptide analog of the endogenous neuropeptide \u03b1-melanocyte-stimulating hormone (\u03b1-MSH). Its primary sequence, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, incorporates a non\u2011proteinogenic amino acid norleucine (Nle) and a side\u2011chain\u2011to\u2011side\u2011chain lactam bridge that stabilizes the bioactive conformation. This structural constraint increases metabolic stability compared to linear \u03b1\u2011MSH fragments and influences receptor\u2011binding kinetics.<\/p>\n
In controlled laboratory settings, bremelanotide acts as a non\u2011selective agonist at four of the five cloned human melanocortin receptors\u2014MC1R, MC3R, MC4R, and MC5R\u2014while showing negligible interaction with MC2R (the ACTH receptor). Binding studies using radioligand displacement assays in transfected cell lines indicate nanomolar affinities at MC1R and MC4R, with slightly lower potencies at MC3R and MC5R. Such broad\u2011spectrum agonism makes the peptide a versatile tool for examining melanocortin\u2011dependent signaling cascades without the confounding selectivity of endogenous agonists.<\/p>\n
Research interest in bremelanotide originally stemmed from investigations into melanocortin pathways in preclinical models, including rodent and non\u2011human primate systems. Early work explored how central MC4R activation could modulate grooming behavior, energy expenditure, and neuroendocrine outputs, while peripheral MC1R activity was studied in relation to melanogenesis in epidermal models. These initial lines of inquiry established a foundation for the compound\u2019s later use as a reference agonist in pharmacological profiling and receptor\u2011structure\u2011function studies.<\/p>\n
When a research organization requires bremelanotide for reproducible in vitro and in vivo investigations, sourcing from a bremelanotide GMP manufacturer becomes a critical quality determinant. Current Good Manufacturing Practices (cGMP) are a regulatory framework that ensures every batch of the peptide meets predefined specifications for identity, purity, and activity. Adherence to cGMP minimizes inter\u2011batch variability that could confound longitudinal studies or multi\u2011site collaborations.<\/p>\n
Facilities that manufacture bremelanotide under GMP conditions are validated across all critical operations: solid\u2011phase peptide synthesis (SPPS), preparative high\u2011performance liquid chromatography (HPLC), lyophilization, and final aseptic filling. Environmental monitoring programs maintain controlled parameters for temperature, humidity, and particulate counts according to ISO 14644 cleanroom standards. Equipment qualification, process validation, and personnel training are documented as part of a robust quality system.<\/p>\n
Complete documentation accompanies every lot. Master and executed batch records detail each synthetic cycle volume, coupling reagent, cleavage time, and purification step. Analytical raw data packages are compiled into a certificate of analysis that is cross\u2011referenced with the original batch record. Stability\u2011indicating studies, often conducted under ICH Q1A guidelines, generate accelerated and long\u2011term data that support shelf\u2011life assignments and proper storage conditions.<\/p>\n
Stringent analytical characterization is a hallmark of a bremelanotide GMP manufacturer. Routinely, each manufactured batch undergoes orthogonal testing: reversed\u2011phase HPLC for purity assessment, high\u2011resolution mass spectrometry (HRMS) for accurate mass confirmation, and amino acid analysis to verify compositional integrity. The chromatographic purity acceptance criterion is typically set at \u226598% peak area by HPLC, with any single impurity limited to \u22641.0%. This high purity threshold safeguards the reproducibility of receptor\u2011binding assays, where minor peptide\u2011related impurities could distort apparent affinity values or trigger off\u2011target signaling.<\/p>\n
Liquid chromatography\u2011mass spectrometry (LC\u2011MS) analysis confirms the monoisotopic mass within 5 ppm of the theoretical value and detects potential oxidation, deamidation, or truncation products. Additionally, peptide content determination by quantitative amino acid analysis or nitrogen content enables precise solution preparation for dose\u2011response studies. For cell\u2011based experiments, microbiological quality is verified through bioburden and endotoxin testing, employing methods from pharmacopoeias such as the USP (United States Pharmacopeia) general chapter . Sterility testing, when performed, follows membrane filtration protocols to confirm the absence of viable microorganisms, a vital parameter for studies in primary cell cultures or organotypic assays.<\/p>\n
Long\u2011term research programs\u2014especially those investigating chronic receptor modulation or requiring pooled data from multiple experimental blocks\u2014depend on batch\u2011to\u2011batch consistency. A bremelanotide GMP manufacturer achieves this by controlling starting materials, resin substitution levels, and cleavage conditions within narrow operational ranges. Multiple consecutive lots can then demonstrate nearly superimposable HPLC chromatograms and consistent biological activity in functional assays, such as cAMP accumulation in MC4R\u2011expressing HEK293 cells.<\/p>\n
For each shipment, a comprehensive Certificate of Analysis (CoA) is provided. The CoA lists appearance (white to off\u2011white lyophilized powder), solubility profile, net peptide content, purity, mass spectral data, and the residual solvent profile as determined by gas chromatography. Stability summaries appended to the CoA indicate the recommended storage temperature (typically \u201320\u202f\u00b0C in a desiccated, light\u2011protected environment) and the validated retest period. This documentation enables principal investigators to integrate the material into institutional standard operating procedures with full traceability.<\/p>\n
Bremelanotide has become a widely cited tool in studies of melanocortin receptor signaling and systemic physiology, entirely within preclinical frameworks. Its ability to simultaneously engage multiple melanocortin subtypes allows researchers to dissect cooperative receptor interactions or to calibrate selective ligands in competition binding experiments. The peptide is frequently employed in cell\u2011based assays to measure receptor activation, receptor internalization dynamics, and the recruitment of intracellular adaptor proteins such as \u03b2\u2011arrestin.<\/p>\n
Beyond receptor pharmacology, the compound serves as a chemical probe in neuroscience, endocrinology, and dermatological research. In rodent brain\u2011slice electrophysiology, bath\u2011applied bremelanotide has been used to examine MC4R\u2011mediated modulation of synaptic transmission. In adipocyte and hepatocyte culture systems, it helps illuminate melanocortin\u2011driven changes in lipid metabolism and gene expression. Across these applications, sourcing from a bremelanotide GMP manufacturer assures that the biological responses observed are attributable to the peptide and not to contaminating synthesis artifacts.<\/p>\n
Bremelanotide\u2019s full pharmacological profile across MC1R, MC3R, MC4R, and MC5R has been established using recombinant cell lines expressing each receptor subtype individually. In GTP\u03b3S binding assays and cAMP accumulation experiments, the peptide displays EC\u2085\u2080 values in the low\u2011 to mid\u2011nanomolar range at MC4R, with somewhat higher concentrations needed for full activation of MC3R and MC5R. This differential selectivity is valuable for mapping the functional topography of the receptor binding pocket through site\u2011directed mutagenesis studies.<\/p>\n
Investigators also utilize the compound to study melanogenesis in cultured human melanocytes, where MC1R agonism upregulates tyrosinase expression and melanin synthesis. In parallel, it aids in understanding the role of MC3R and MC4R in appetite regulation and energy expenditure\u2014areas probed using hypothalamic cell lines and whole\u2011animal calorimetry. Furthermore, the involvement of MC5R in exocrine gland function and immune cell modulation is explored by applying bremelanotide to isolated sebocytes and macrophage cultures, providing insights into inflammation\u2011related signaling networks.<\/p>\n
At the intracellular level, bremelanotide acts through G\u03b1s\u2011coupled melanocortin receptors to stimulate adenylyl cyclase and raise cyclic AMP (cAMP) concentrations. This canonical pathway can be tracked with real\u2011time cAMP biosensors, allowing kinetic analysis of receptor activation and desensitization. In addition to the cAMP\u2011protein kinase A axis, sustained agonism by bremelanotide has been shown to engage the MAPK\/ERK cascade, likely via cAMP\u2011dependent and \u2011independent cross\u2011talk mechanisms. In PC12 and HEK293 models, ERK1\/2 phosphorylation can be monitored by western blotting after defined exposure intervals, offering a more integrative readout of signaling output.<\/p>\n
Because bremelanotide binds multiple receptor subtypes, it is often used as a broad\u2011spectrum agonist to benchmark the signaling signatures of newer, subtype\u2011selective peptides. Researchers pair the compound with inhibitors of G protein\u2011coupled receptor kinases (GRKs) or \u03b2\u2011arrestin to dissect biased signaling modes. Such experiments rely on the consistent potency and purity delivered by a bremelanotide GMP manufacturer, as even minor shifts in peptide content could alter the calculated bias factor between G\u2011protein and \u03b2\u2011arrestin endpoints.<\/p>\n
Procurement teams seeking a bremelanotide GMP manufacturer should assess several pillars of reliability: certification status, facility auditing history, and the completeness of the quality dossier. A reputable supplier will be able to provide a master file that includes a process flow diagram, cleaning validation reports, and an overview of the analytical methods. An on\u2011site or virtual audit may further confirm that the facility\u2019s material and personnel flow prevents cross\u2011contamination and that data integrity principles are embedded in all laboratory information systems.<\/p>\n
Traceability extends from the activated amino acid reagents through to the final packaged vial. A GMP\u2011compliant supply chain incorporates vendor qualification programs, incoming raw material testing, and full lot\u2011number linkage across the synthesis, purification, and dispensing stages. For projects with non\u2011standard requirements, many manufacturers offer custom synthesis services\u2014modifying scale, packaging configuration, or providing fully characterized reference standards\u2014while maintaining the same GMP quality framework.<\/p>\n
A credible bremelanotide GMP manufacturer operates under a quality management system that aligns with internationally recognized standards. Facilities may be certified in accordance with World Health Organization (WHO) GMP guidelines, relevant parts of the U.S. Code of Federal Regulations (21 CFR 210\/211), or EU GMP Annexes for active pharmaceutical ingredients (ICH Q7). Many add ISO 9001:2015 certification to demonstrate a process\u2011based quality management approach that drives continuous improvement.<\/p>\n
In parallel, environmental and ethical responsibilities are addressed through documented compliance with local safety and environmental regulations, as well as through supplier codes of conduct that prohibit forced labor and ensure fair working conditions. For academic and industry researchers, these certifications translate into a reliable procurement pathway that meets the due\u2011diligence requirements of their institutional biosafety and grants offices. Audit reports and certification renewals are typically made available under a confidentiality agreement.<\/p>\n
Global distribution of a lyophilized research peptide demands a logistics framework that preserves structural integrity. A bremelanotide GMP manufacturer uses temperature\u2011controlled packaging\u2014often insulated containers with validated cool packs\u2014that maintain the product below 25\u202f\u00b0C during transit. Shipment monitoring devices, such as temperature data loggers, can be included to verify cold\u2011chain continuity. Packaging also safeguards against light exposure and moisture ingress, with sealed glass vials over\u2011wrapped in foil or opaque pouches.<\/p>\n
For high\u2011throughput screening or multi\u2011year studies, bulk quantities (multi\u2011gram to kilogram scale) are available under the same GMP quality system. The ordering process is typically supported by a secure online platform that includes live inventory checks, lot\u2011specific product information, and the option to request a letter of authorization for import permits. The manufacturer provides commercial invoices, packing lists, and certificates of origin required by customs, simplifying the onboarding of bremelanotide into research institutions worldwide.<\/p>\n
Research use only note:<\/strong> All products, including bremelanotide, are intended solely for laboratory research purposes. They are not intended for human or veterinary applications and may not be used as any form of clinical agent or in any diagnostic procedure. The information provided is for scientific and educational reference only.<\/p>\n For research use only. Not for human or veterinary use.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" About Bremelanotide \u2013 Research Background Bremelanotide is a synthetic cyclic heptapeptide analog of the endogenous neuropeptide \u03b1-melanocyte-stimulating hormone (\u03b1-MSH). Its primary sequence, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, incorporates a non\u2011proteinogenic amino acid norleucine (Nle) and a side\u2011chain\u2011to\u2011side\u2011chain lactam bridge that stabilizes the bioactive conformation. This structural constraint increases metabolic stability compared to linear \u03b1\u2011MSH fragments and influences receptor\u2011binding kinetics. […]<\/p>\n","protected":false},"author":1,"featured_media":1492,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"news_category":[],"class_list":["post-1491","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n